Indeed, the blockade of the CCL2/CCR2 axis, in both a preclinical model of CAC and a genetic model of intestinal tumorigenesis (ApcMin mice), leads to the reduction of TAMs in association with significant inhibition of tumor multiplicity and growth [59,60]. The gene discussed is CCL2; the disease is neoplasm.